Ondine Biomedical Inc on Wednesday celebrated results from a new study showing that its Steriwave treatment dramatically reduced levels of antibiotic-resistant bacteria.

Shares in Ondine were up 69% at 15.60 pence in London on Wednesday morning.

The Vancouver-based life sciences company said that according to the controlled in vitro study, treatment with Steriwave photodisinfection reduced the amount of viable bacteria by over 99.9% compared to the control group.

Ondine said the study was evaluating Steriwave’s efficacy against Gram-negative and Gram-positive multidrug-resistant and extensively drug-resistant bacteria with novel antibiotic resistance factors. These included ‘some of the most commonly prescribed antibiotic classes’ including penicillin.

The study ‘concluded that photodisinfection is likely an important adjunct to AMR strategies in the future and that further clinical studies are warranted,’ Ondine said.

Ondine will present the study results on Wednesday afternoon at the IP2023 annual conference in Liverpool.

‘We continue to demonstrate, both clinically in hospitals across Canada and in the lab, that photodisinfection can provide a real alternative to topical antimicrobials...this technology can save millions of lives,’ proclaimed Chief Executive Officer Carolyn Cross.

She added: ‘The results of this study are particularly welcome as we prepare for our US Phase 3 trial in partnership with HCA Healthcare who are providing invaluable guidance and support.’

Copyright 2023 Alliance News Ltd. All Rights Reserved.